• For certain indications, the Moderna COVID‑19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by the FDA, under an Emergency Use Authorization (EUA), to prevent Coronavirus Disease 2019 (COVID‑19) in individuals 18 years of age and older. There are two presentations/formulations of the Moderna COVID‑19 Vaccine authorized for use.

  • The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner.

See below for Moderna COVID‑19 Vaccine authorized uses.

Sign up to receive updates from Moderna

Vaccine Overview for
Vaccination Providers

Primary Series Vaccination

Looking for information on adult primary series vaccination?

Visit HCP site for spikevax
(COVID‑19 vaccine, mRNA)
Primary series 1 month between shots
Booster doses at least 5 months after completing primary series and at least 4 months after first booster dose

Booster Dose

The booster dose of the Moderna COVID‑19 Vaccine may be administered from two different vial presentations. When using the 5.5 or 7.5 mL multiple-dose vial with a red cap and a label with a light blue border, the dose is 0.25 mL. When using the booster-only multiple-dose vial with a dark blue cap and a label with a purple border, the booster dose is 0.5 mL.

A first Moderna COVID‑19 Vaccine booster dose may be administered intramuscularly at least 5 months after completing a primary series of the Moderna COVID‑19 Vaccine or spikevax (COVID-19 Vaccine, mRNA) to individuals 18 years of age or older.

A first booster dose of the Moderna COVID‑19 Vaccine may be administered to individuals 18 years of age and older as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.

A second booster dose of the Moderna COVID‑19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine.

A second booster dose of the Moderna COVID‑19 Vaccine may be administered at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine to individuals 18 years of age and older with certain kinds of immunocompromise.

See clinical trial data from booster dose study

Third Dose for Immunocompromised Individuals

A third primary series dose of the Moderna COVID‑19 Vaccine (0.5 mL) at least 1 month following the second dose is authorized for administration to individuals at least 18 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

A second booster dose at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine is also available for individuals 18 years of age and older with certain kinds of immunocompromise.

Learn more about vaccination for immunocompromised individuals
COVID-19 Moderna Vaccine packaging, both 11 and 15 dose.

About the Moderna COVID‑19 Vaccine

The vaccine was developed by Moderna, a biotechnology company that has focused on mRNA technology since 2010, and is currently being studied in a large Phase 3 trial.

Learn more about the Moderna COVID‑19 Vaccine

Storage & Handling

The Moderna COVID‑19 Vaccine multiple‑dose vials are stored frozen between -50°C to -15°C (-58°F to 5°F). During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

Vials can be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30 days prior to first use.

How to properly store and handle
5.5 mL vial for primary series doses or booster doses

5.5 mL vial for primary series doses or booster doses

2.5 mL vial for booster dose only

2.5 mL vial for booster dose only

Dosing & Administration

The Moderna COVID‑19 Vaccine is administered as a primary series by intramuscular injection of two doses (0.5 mL each) 1 month apart to individuals 18 years of age or older.

A third primary series dose of the Moderna COVID‑19 Vaccine (0.5 mL) at least 1 month following the second dose is authorized for administration to individuals at least 18 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

The booster dose of Moderna COVID-19 Vaccine may be administered from two different vial presentations. When using the 5.5 mL multiple-dose vial with a red cap and a label with a light blue border, the dose is 0.25 mL. When using the booster-only multiple-dose vial with a dark blue cap and a label with a purple border, the booster dose is 0.5 mL.

A first Moderna COVID‑19 Vaccine booster dose may be administered intramuscularly at least 5 months after completing a primary series of the Moderna COVID‑19 Vaccine or spikevax (COVID-19 Vaccine, mRNA) to individuals 18 years of age or older.

A first booster dose of the Moderna COVID‑19 Vaccine may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.

A second booster dose of the Moderna COVID‑19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine.

A second booster dose of the Moderna COVID‑19 Vaccine may be administered at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine to individuals 18 years of age and older with certain kinds of immunocompromise.

Get full dosing details

Clinical Trial Data

The Moderna COVID‑19 Vaccine is being evaluated in an ongoing Phase 3 randomized, placebo‑controlled, observer‑blind clinical trial conducted in the United States.

See clinical trial data

Frequently Asked Questions

Take a look at our answers to the questions we hear most often from healthcare professionals.

View all FAQs